The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder

Introduction: Major depressive disorder (MDD) is the leading cause of disability worldwide, and according to the STAR*D trial, only 33% of patients with MDD responded to initial drug therapy. Augmentation of the leading class of antidepressant treatment, selective serotonin reuptake inhibitors (SSRI...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahli, Zeyad T., Banerjee, Pradeep, Tarazi, Frank I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Drug Discovery Case History
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841022/
https://www.ncbi.nlm.nih.gov/pubmed/26971593
http://dx.doi.org/10.1517/17460441.2016.1160051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841022/
https://www.ncbi.nlm.nih.gov/pubmed/26971593
http://dx.doi.org/10.1517/17460441.2016.1160051

Ejemplares similares